bpc-157 clinical trials safety Preclinical evaluation of body protective compound-157, a potential drug for treating various wounds The Hidden Risks of BPC‑157:

Because the medication is still being studied, there will always be known and unknown risks

Experimental work examining angiogenic responses during muscle and tendon healing reported increased expression of angiogenesis-associated markers such as vascular endothelial growth factor (VEGF), CD34, and factor VIII within injured tissues following BPC-157 exposure [6]

For example, if a vial contains a known total amount of peptide and it is reconstituted with 2 mL of bacteriostatic water, then dividing the total by 2 gives the concentration per mL

Clinically, they are being explored for their potential to accelerate postoperative recovery, support chronic soft-tissue healing, and improve tendon-to-bone integration following procedures such as rotator cuff repair and ACL reconstruction

Do I Need an Appointment

The first is potential selection bias, as we were only able to contact 11 out of 23 subjects to complete the SCAR-Q survey